6VVU image
Deposition Date 2020-02-18
Release Date 2020-12-30
Last Version Date 2024-11-06
Entry Detail
PDB ID:
6VVU
Title:
Anti-Tryptase fab E104.v1 bound to tryptase
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
3.00 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Tryptase alpha/beta-1
Gene (Uniprot):TPSAB1
Chain IDs:A, B, C (auth: D), D (auth: C)
Chain Length:275
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Fab E104.v1 heavy chain
Chain IDs:E, G, H, J
Chain Length:230
Number of Molecules:4
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Fab E104.v1 light chain
Chain IDs:F, I, K, L
Chain Length:217
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
Bivalent antibody pliers inhibit beta-tryptase by an allosteric mechanism dependent on the IgG hinge.
Nat Commun 11 6435 6435 (2020)
PMID: 33353951 DOI: 10.1038/s41467-020-20143-x

Abstact

Human β-tryptase, a tetrameric trypsin-like serine protease, is an important mediator of allergic inflammatory responses in asthma. Antibodies generally inhibit proteases by blocking substrate access by binding to active sites or exosites or by allosteric modulation. The bivalency of IgG antibodies can increase potency via avidity, but has never been described as essential for activity. Here we report an inhibitory anti-tryptase IgG antibody with a bivalency-driven mechanism of action. Using biochemical and structural data, we determine that four Fabs simultaneously occupy four exosites on the β-tryptase tetramer, inducing allosteric changes at the small interface. In the presence of heparin, the monovalent Fab shows essentially no inhibition, whereas the bivalent IgG fully inhibits β-tryptase activity in a hinge-dependent manner. Our results suggest a model where the bivalent IgG acts akin to molecular pliers, pulling the tetramer apart into inactive β-tryptase monomers, and may provide an alternative strategy for antibody engineering.

Legend

Protein

Chemical

Disease

Primary Citation of related structures